Public hearings as a transparency measure: The Valproate case

Research output: Contribution to conference › Conference abstract for conference › Research

Standard

Public hearings as a transparency measure: The Valproate case. / Møllebæk, Mathias.

2017.

Research output: Contribution to conference › Conference abstract for conference › Research

Harvard

Møllebæk, M 2017, 'Public hearings as a transparency measure: The Valproate case'.

APA

Møllebæk, M. (2017). Public hearings as a transparency measure: The Valproate case.

Vancouver

Møllebæk M. Public hearings as a transparency measure: The Valproate case. 2017.

Author

Møllebæk, Mathias. / Public hearings as a transparency measure: The Valproate case.

Bibtex

@conference{065faefee0a84a21ad7457b3c7752e0e,
title = "Public hearings as a transparency measure: The Valproate case",
abstract = "In line with increasing calls of transparency initiatives across European institutions, the European Medicines Agency (EMA) will on September 26th 2017 host its first public hearing on the regulatory of a drug, namely Valproate. According to the EMA website, the public hearing is intended to “increase transparency by opening up the scientific evaluation process” and “[give citizens] a voice in the evaluation of medicines.” This conference paper will present the preliminary results from a rhetorical analysis of the public hearing as a transparency measure. What kind transparency does a public hearing provide? How are citizens{\textquoteright} accounts positioned vis-{\`a}-vis expert testimonies? Does the public hearing achieve sufficient “hybridity” of its heterogeneous stakeholder group? ",
author = "Mathias M{\o}lleb{\ae}k",
year = "2017",
month = oct,
day = "2",
language = "English",

}

RIS

TY - ABST

T1 - Public hearings as a transparency measure: The Valproate case

AU - Møllebæk, Mathias

PY - 2017/10/2

Y1 - 2017/10/2

N2 - In line with increasing calls of transparency initiatives across European institutions, the European Medicines Agency (EMA) will on September 26th 2017 host its first public hearing on the regulatory of a drug, namely Valproate. According to the EMA website, the public hearing is intended to “increase transparency by opening up the scientific evaluation process” and “[give citizens] a voice in the evaluation of medicines.” This conference paper will present the preliminary results from a rhetorical analysis of the public hearing as a transparency measure. What kind transparency does a public hearing provide? How are citizens’ accounts positioned vis-à-vis expert testimonies? Does the public hearing achieve sufficient “hybridity” of its heterogeneous stakeholder group?

AB - In line with increasing calls of transparency initiatives across European institutions, the European Medicines Agency (EMA) will on September 26th 2017 host its first public hearing on the regulatory of a drug, namely Valproate. According to the EMA website, the public hearing is intended to “increase transparency by opening up the scientific evaluation process” and “[give citizens] a voice in the evaluation of medicines.” This conference paper will present the preliminary results from a rhetorical analysis of the public hearing as a transparency measure. What kind transparency does a public hearing provide? How are citizens’ accounts positioned vis-à-vis expert testimonies? Does the public hearing achieve sufficient “hybridity” of its heterogeneous stakeholder group?

M3 - Conference abstract for conference

ER -

ID: 184327103